Selenium supplementation does not decrease thyroid peroxidase antibody concentration in children and adolescents with autoimmune thyroiditis
W Bonfig, R Gärtner, H Schmidt, W Bonfig, R Gärtner, H Schmidt
Abstract
In adults, selenium supplementation decreases thyroid peroxidase antibody (TPO Ab) concentrations in patients with autoimmune thyroiditis (AIT). Our aim in this study was to investigate if selenium supplementation decreased TPO Ab and thyroglobulin antibody (Tg Ab) concentrations in children with AIT. Forty-nine patients (33 females) with newly diagnosed AIT and hypothyroidism were randomized to daily oral therapy with levothyroxine alone (group A, n=18), levothyroxine plus 100 microg sodium-selenite (group B, n=13), or levothyroxine plus 200 microg sodium-selenite (group C, n=18). Mean age at diagnosis was 12.2+/-2.2 years. All 49 patients needed a mean levothyroxine dose of 1.6+/-0.5 microg/kg body weight to lower TSH to the treatment goal of 1-2 microU/ml, with no significant difference between groups. At study entry and after 12 months, TPO Ab concentrations were comparable in all three groups. Tg Ab concentrations decreased significantly after 12 months in group A and group C (p=0.03 and p=0.01), but not in group B (p=0.06). It is our conclusion that selenium supplementation with sodium-selenite does not decrease TPO Ab concentrations in children and adolescents, neither given in the reduced dose of 100 microg daily nor given in the "adult" supplementation dose of 200 microg daily.
Source: PubMed
Aankomende klinische onderzoeken
-
NCT07826949Nog niet aan het wervenGlioom | Hersenen neoplasma | Terugkerende hooggradige gliomen
-
NCT07826962Nog niet aan het wervenBetrokkenheid van de patiënt
-
NCT07826975Nog niet aan het werven
-
NCT07826988Nog niet aan het wervenSikkelcelziekte | Vaso-occlusieve crisis
-
NCT07827001WervingHersenkanker | Kanker van het CZS | Kanker van het zenuwstelsel | Hersenkanker Uitgezaaid
-
NCT07827027Nog niet aan het wervenFundamentele wetenschap
-
NCT07827040WervingVolwassenen | Digitale assistentie voor slechtzienden | Visuele beperkingen
-
NCT07827053Nog niet aan het wervenDuctaal adenocarcinoom van de alvleesklier (PDAC)
-
NCT07827066Nog niet aan het wervenStoppen met roken | AI-agent | Early-Stage Cancer
-
NCT07827131Nog niet aan het werven